What are the targets of regorafenib?

Regorafenib (Regorafenib) is a multi-target targeted therapy drug that mainly acts on multiple signaling pathways in tumor cells to inhibit tumor growth, spread and angiogenesis. The following are the main targets and effects of regorafenib :

1.Vascular endothelial growth factor receptor (VEGFR): Regofenib inhibitsVEGFR activity and blocks vascular endothelial growth factor (VEGF) signaling during tumor angiogenesis, thereby inhibiting tumor angiogenesis and nutrient supply, and reducing tumor growth and metastasis.

2.Platelet-derived growth factor receptor (PDGFR): PDGFR is another important receptor related to tumor angiogenesis. Regofenib can inhibit PDGFR activity, thereby reducing the formation and stability of tumor blood vessels, thereby blocking the blood supply to the tumor.

3.Mitogen-activated protein kinase (RAF): RAF is a key component of the mitogen-activated protein kinase signaling pathway and is involved in regulating cell growth and proliferation. Regofenib blocks the conduction of this signaling pathway by inhibiting RAF activity, thereby inhibiting the proliferation and growth of tumor cells.

4.RETReceptor tyrosine kinase: RETReceptor tyrosine kinase plays an important role in the occurrence and development of some tumors. Regofenib can inhibitRET receptor tyrosine kinase activity, thereby blocking the growth and spread of related tumor cells.

5.KITReceptor tyrosine kinase: KITReceptor tyrosine kinase is a receptor tyrosine kinase associated with a variety of tumors. Regorafenib can inhibitKIT receptor tyrosine kinase activity, thereby inhibiting the growth and proliferation of related tumor cells.

In general, Regorafenib plays an anti-tumor role by acting on multiple targets, including angiogenesis pathways and cell proliferation pathways, comprehensively inhibiting tumor growth, metastasis and angiogenesis. This multi-target mode of action makes regorafenib an effective treatment option, especially for patients who are refractory to or poorly tolerated by other treatments.